Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,252.80
(
-1.87%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
79,046.02
(
-0.02%
)
News Focus
News Focus
Post# of 257578
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 146402

Thursday, 08/23/2012 9:34:11 AM

Thursday, August 23, 2012 9:34:11 AM

Post# of 257578
GSK/JNJ start phase-3 RA trials for Sirukumab:

http://www.reuters.com/article/2012/08/23/us-johnsonjohnson-gsk-drugtrial-idUSBRE87M0H420120823

One phase-3 trial is in the second-line setting (following MTX) and one is effectively in the third-line setting (following a TNF-a drug). Both trials have placebo as the comparator, but only the third-line trial has radiographic progression as an endpoint.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today